AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, Shows High Potency and Sensitivity in Preclinical Models of Small-Cell Lung Cancer.
Michael J GiffinKeegan CookeEdward K LobenhoferJuan EstradaJinghui ZhanPetra DeegenMelissa ThomasChristopher M MurawskyJonathan WernerSiyuan LiuFei LeeOliver HomannMatthias FriedrichJoshua T PearsonTobias RaumYajing YangSean CaenepeelJennitte StevensPedro J BeltranJude CanonAngela CoxonJulie M BailisPaul E HughesPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
AMG 757 has a compelling safety and efficacy profile in preclinical studies making it a viable option for targeting DLL3-expressing SCLC tumors in the clinical setting.